Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Cash from Financing Activities (2020 - 2025)

BioAtla (BCAB) has disclosed Cash from Financing Activities for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 27.92% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $6.3 million, down 34.01%, while the annual FY2025 figure was $6.3 million, 34.01% down from the prior year.
  • Cash from Financing Activities hit $6.7 million in Q4 2025 for BioAtla, up from -$6000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $75.1 million in Q3 2021 and bottomed at -$3.9 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $7.3 million, with a median of -$13500.0 recorded in 2024.
  • Year-over-year, Cash from Financing Activities soared 7726.05% in 2024 and then crashed 2938.46% in 2025.
  • BioAtla's Cash from Financing Activities stood at -$3.9 million in 2021, then skyrocketed by 1680.48% to $61.8 million in 2022, then tumbled by 99.81% to $119000.0 in 2023, then skyrocketed by 7726.05% to $9.3 million in 2024, then fell by 27.92% to $6.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $6.7 million, -$6000.0, and -$36000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.